Figure 3.

A, waterfall plot of best response of 44 patients who received bardoxolone methyl. Best overall response was categorized as progressive disease (black bars), stable disease (blue bars), partial response or complete response (both red bars). “c” represents patients who exhibited clinical progression but were not restaged by RECIST/WHO. B, images of a patient with anaplastic thyroid cancer who responded to bardoxolone methyl after cycle 2 (best response −69%) and stayed on protocol for 18 months. Left panel is the image taken at baseline; right panel is the image of the same patient taken after two cycles of treatment.